CJC-1295 / Ipamorelin 10mg
Product Information
Label / Documentation
Verify Amino Research product information and COA documentation through the Amino Research verification page at aminoresearch.net.
CJC-1295 / Ipamorelin 10mg
CJC-1295 / Ipamorelin 10mg is a two-component catalog blend; the current report identifies CJC-1295 no DAC and Ipamorelin. Published animal work has examined an albumin-binding long-acting CJC-1295 analog in GHRH-knockout mice, while separate work characterized ipamorelin in rat pituitary cells, rats, and swine.
Those sources describe different component research systems. The cited CJC-1295 form is not established as equivalent to the report-listed no-DAC component, and neither source establishes combined effects, safety, efficacy, an approved indication, or suitability for human or animal use. This material is supplied only for laboratory research, with no dosing or administration guidance.
Documentation note: The product name uses CJC-1295, while the current report identifies that component as CJC-1295 no DAC. The 5 mg / 5 mg split comes from the report specification. Published long-acting CJC-1295 research is related context and is not treated as evidence of equivalence to the no-DAC component.
Research sources
- Alba et al.: CJC-1295 in GHRH-knockout mice — animal research on an albumin-binding long-acting CJC-1295 analog; not evidence of no-DAC equivalence.
- Raun et al.: ipamorelin in pituitary-cell and animal systems — rat pituitary cells plus rat and swine experiments.
Documentation and related records
Documentation status: Purity + Endotoxin COA.
Review the current CJC-1295 / Ipamorelin 10mg documentation for lot HEL-3437208, the testing and COA guidance, and the Research Use Only compliance information. For adjacent catalog records, see Tesamorelin 10mg, Ipamorelin 10mg, Sermorelin 5mg. These links support catalog navigation and do not imply equivalence or use.
CJC-1295 / Ipamorelin 10mg — Specifications
Testing & documentation for CJC-1295 / Ipamorelin 10mg
The current combined third-party report identifies CJC-1295 / Ipamorelin 10mg for lot HEL-3437208 and reports tested content and purity separately for each listed component plus one shared endotoxin result. No aggregate component total or purity is inferred; researchers should review the literal component results and documentation note.
Only documented test categories are shown. Where a value is not yet published it is shown as “Available on documentation” or “Pending.”
For laboratory research use only
CJC-1295 / Ipamorelin 10mg is intended solely for laboratory research use by qualified research professionals. It is not for human or animal consumption and is not intended for diagnostic, therapeutic, or clinical use. No dosing or administration guidance is provided. Researchers are responsible for compliance with all applicable laws and regulations. Review Amino Research compliance and RUO information.
How Amino Research materials are supplied
Purity + Endotoxin COA
Current documentation identifies lot HEL-3437208 for this CJC-1295 / Ipamorelin 10mg record.
Component-Specific Purity
The current report lists a separate UPLC/MS purity result for each component.
Component Test Results
Labeled content and literal tested-content results are disclosed separately for every component.
RUO Documentation
COA access and clear research-only limitations are linked from this product record.
CJC-1295 / Ipamorelin 10mg
Add this research-use material to your cart, or review its documentation. Pricing reflects current Amino Research pricing.
CJC-1295 / Ipamorelin 10mg — FAQ
What separate research context is available for the CJC-1295 and Ipamorelin components?
Published work examined an albumin-binding long-acting CJC-1295 analog in GHRH-knockout mice and separately characterized ipamorelin in rat pituitary cells, rats, and swine. The CJC-1295 source does not establish equivalence to the report-listed no-DAC component, and neither source establishes effects or an approved use for the blend.
What does the current CJC-1295 / Ipamorelin 10mg COA document?
The current combined third-party report for lot HEL-3437208 provides component-specific results: CJC-1295 no DAC — labeled 5 mg, tested content 4.9 mg, purity 99.36%; Ipamorelin — labeled 5 mg, tested content 4.9 mg, purity 99.28%. The shared blend endotoxin result is < 0.05 EU/mL. No aggregate purity or tested-content total is inferred. Documentation note: The product name uses CJC-1295, while the current report identifies that component as CJC-1295 no DAC. The 5 mg / 5 mg split comes from the report specification. Published long-acting CJC-1295 research is related context and is not treated as evidence of equivalence to the no-DAC component. Review the complete lot-specific PDF.
How should researchers verify this documentation?
Match the product name and lot on the vial to the report, then review the method, purity, tested content, endotoxin result, and report date. See the testing and COA guidance and the COA Library.
Is CJC-1295 / Ipamorelin 10mg intended for human or animal use?
No. It is supplied solely for laboratory research use by qualified research professionals. It is not for human or animal consumption and is not intended for diagnostic, therapeutic, or clinical use. No dosing or administration guidance is provided. Review the RUO and compliance information.
Which related Amino Research records can be reviewed?
Researchers can review Tesamorelin 10mg, Ipamorelin 10mg, Sermorelin 5mg. These links are provided for catalog navigation, not as equivalence or use claims.
Lab Documentation & Batch Records
Amino Research retains identity, purity, and endotoxin documentation organized by lot, and adds new records as additional batches are tested. The newest report is the current documentation; earlier reports are retained as batch history. Third-party tested. For laboratory research use only.
Research Use Only. Documentation is provided for identity and quality verification for laboratory research use only. Not for human or animal consumption.
